Drugs / SYHA136
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04036656 | Aug 2019 → Jan 2020 | venous thromboembolism | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-04-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NEW ORAL ANTI-COAGULANT DRUG "SYHA136" WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-04-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NEW ORAL ANTI-COAGULANT DRUG "SYHA136" WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHA136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04036656 ↗ |
| Action | Inhibit | “Direct Coagulation Factor Xa Inhibitor” NCT04036656 ↗ |
| Route | Oral | “single oral dose of SYHA136 0.5 mg” NCT04036656 ↗ |